期刊文献+

2例肥胖患者优化氟康唑给药方案的病例报道并文献分析

Two cases of optimal fluconazole administration in obese patients and literature analysis
下载PDF
导出
摘要 目的 :探讨肥胖患者氟康唑的给药方案,为临床合理用药提供依据。方法 :通过检索Medline、Pub Med、Springer数据库,中国学术期刊全文数据库(CNKI)、万方数据库和维普中文科技期刊数据库(VIP),收集有关肥胖患者使用氟康唑的药代动力学和临床疗效资料,进行回顾性分析。临床药师通过体质量校正,计算给药剂量,为2例隐球菌肺炎的肥胖患者优化氟康唑给药方案,观察治疗效果和不良反应。结果 :2例患者均取得了良好的治疗效果,均未发生药物不良反应。结论 :结合体质量和药代动力学参数,优化肥胖患者氟康唑的给药方案,能够提高临床疗效和用药安全性。 Objective:To analyze the dosage regimens of fluconazole in obese patients and provide reference for the safety of clinical medication.Methods:The pharmacokinetics and clinical efficacy data of fluconazole in two obese patients were collected and retrospectively analyzed by searching Medline,PubMed,Springer database,CNKI,Wanfang database and VIP database.Clinical pharmacists calculated the dose of fluconazole by body weight correction,optimized the fluconazole administration scheme for two obese patients with cryptococcus pneumonia,and observed the therapeutic effect and adverse reactions.Results:Both patients achieved good therapeutic effect and no adverse drug reaction occurred.Conclusion:Combining body weight and pharmacokinetic parameters and optimizing fluconazole administration regimen in obese patients can improve clinical efficacy and medication safety.
作者 余淼 褚娜英 刘源 蒋爽 YU Miao;CHU Naying;LIU Yuan;JIANG Shuang(Department of Pharmacy,the First People’s Hospital of Shangqiu City,Shangqiu 476100,China;Department of Emergency Intensive Care Unit,the First People’s Hospital of Shangqiu City,Shangqiu 476100,China)
出处 《上海医药》 CAS 2023年第1期65-68,共4页 Shanghai Medical & Pharmaceutical Journal
关键词 氟康唑 肥胖患者 给药方案优化 疗效 fluconazole obese patients dosing regimen optimization effectiveness
  • 相关文献

参考文献3

二级参考文献28

  • 1Ashley ESD, Lewis R, Lewis JS, et al. Pharmacology of sys-temic antifungal agents [ J ]. Clin Inf Dis,2006,43 ( Supple-ment 1) :S28 -S39.
  • 2Zimmermann T, Yeates R,Laufen H,et al. Influence of con-comitant food intake on the oral absorption of two triazole an-tifungal agents,itraconazole and fluconazole[ J]. Eur J ClinPharmacol, 1994,46(2) :147 -150.
  • 3Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole onthe pharmacokinetics of itraconazole [ J ]. Eur J Clin Pharma-col, 1998 ,54(2) :159-161.
  • 4Peer A,Woestenborghs R, Heykants J, et al. The effects offood and dose on the oral systemic availability of itraconazolein healthy subjects [ J ]. Eur J Clin Pharmacol, 1989,36(4):423 -426.
  • 5Barone JA, Moskovitz BL, Guamieri J, et al. Enhanced bio-availability of itraconazole in hydroxypropylp — cyclodextrinsolution versus capsules in healthy volunteers [ J ]. Antimi-crob Agents Chemother, 1998,42(7) : 1862 - 1865.
  • 6Johnson MD, Hamilton CD,Drew RH, et al. A randomizedcomparative study to determine the effect of omeprazole onthe peak serum concentration of itraconazole oral solution[J]. J Antimicrob Chemother,2003 ,51(2) :453 -457.
  • 7Foulds G,Brennan D,Wajszczuk C,et al. Fluconazole pene-tration into cerebrospinal fluid in humans [ J ]. J Clin Pharma-col, 1988,28(4) :363 -366.
  • 8Atkinson AJ,Bennett JE. Amphotericin B pharmacokineticsin humans [ J ]. Antimicrob Agents Chemother, 1978,13(2):271 -276.
  • 9Murdoch D,Plosker GL. Anidulafungin[ M]. Drugs,2004,64(19):2249-2258.
  • 10Cherif H,Kalin M, Bjorkholm M. Antifungal therapy in pa-tients with hematological malignancies : how to avoid over-treatment [J ]. Eur J Haematol, 2006,77(4) :288 -292.

共引文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部